CAS 148031-34-9
:Eptifibatide
Description:
Eptifibatide is a synthetic cyclic heptapeptide that functions as a potent inhibitor of platelet aggregation. It is primarily used in clinical settings to prevent thrombotic events in patients undergoing percutaneous coronary interventions or those with acute coronary syndromes. Eptifibatide works by selectively binding to the glycoprotein IIb/IIIa receptor on platelets, thereby blocking the binding of fibrinogen and other adhesive molecules, which is crucial for platelet aggregation. This action helps to reduce the risk of blood clots. The substance is administered intravenously and has a relatively short half-life, necessitating careful monitoring and dosage adjustments. Eptifibatide is generally well-tolerated, but potential side effects may include bleeding complications, thrombocytopenia, and allergic reactions. Its efficacy and safety profile make it a valuable therapeutic agent in cardiology, particularly in acute care settings. As with any medication, its use should be guided by clinical protocols and individual patient considerations.
Formula:C35H49N11O9S2
InChI:InChI=1/C35H49N11O9S2/c36-31(52)26-17-57-56-12-10-27(47)43-22(7-3-4-11-39-35(37)38)32(53)41-16-28(48)44-25(14-29(49)50)34(55)45-24(13-18-15-40-20-6-2-1-5-19(18)20)30(51)21-8-9-23(42-21)33(54)46-26/h1-2,5-6,15,21-26,40,42H,3-4,7-14,16-17H2,(H2,36,52)(H,41,53)(H,43,47)(H,44,48)(H,45,55)(H,46,54)(H,49,50)(H4,37,38,39)/t21?,22-,23-,24-,25-,26-/m0/s1
SMILES:c1ccc2c(c1)c(C[C@H]1C(=O)C3CC[C@@H](C(=N[C@@H](CSSCCC(=N[C@@H](CCCCNC(=N)N)C(=NCC(=N[C@@H](CC(=O)O)C(=N1)O)O)O)O)C(=N)O)O)N3)c[nH]2
Synonyms:- [3-carbamoyl-11-{4-[(diaminomethylidene)amino]butyl}-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
- [(1S,4R,12S,18S,21S)-12-(4-carbamimidamidobutyl)-4-carbamoyl-21-(1H-indol-3-ylmethyl)-2,10,13,16,19,22-hexaoxo-6,7-dithia-3,11,14,17,20,26-hexaazabicyclo[21.2.1]hexacos-18-yl]acetic acid
- Map-Lys-Gly-Asp-Trp-Pro-Cys-Nh2
- Integrelin
- N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide
- [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid
- Eptifibatide Acetate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
2-((3R,11S,17S,20S,25aS)-20-((1H-indol-3-yl)methyl)-3-carbamoyl-11-(4-guanidinobutyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2]dithia[5,8,11,14,17,20]hexaazacyclotricosin-17-yl)acetic acid
CAS:Formula:C35H49N11O9S2Purity:98%Color and Shape:SolidMolecular weight:831.9619Eptifibatide
CAS:Eptifibatide is an antiplatelet, a cyclic heptapeptide made of 6 amino acids and a mercaptopropionyl.Formula:C35H49N11O9S2Purity:98%Color and Shape:White PowderMolecular weight:831.96Eptifibatide acetate
CAS:<p>Eptifibatide acetate is a synthetic cyclic heptapeptide, which is derived from a disintegrin protein found in the venom of the southeastern pygmy rattlesnake, Sistrurus miliarius barbouri. This compound functions as a potent inhibitor of platelet aggregation by competitively binding to the glycoprotein IIb/IIIa receptor on the platelet surface. This receptor plays a critical role in the final common pathway of platelet aggregation by facilitating fibrinogen cross-linking between platelets.</p>Formula:C35H49N11O9S2Purity:Min. 95%Molecular weight:832 g/mol


